drugset / Trial / NCT03817658
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC
Phase 2
Unknown
725 enrolled
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 vs placebo as consolidation chemotherapy after radical concurrent chemoradiotherapy for unresectable locally advanced ESCC.
Timeline
- Start
- 2019-10
- Primary completion
- 2020-10
- Completion
- 2021-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |